Chronic Heart Failure: Contemporary Diagnosis and Management

被引:169
作者
Ramani, Gautam V. [1 ]
Uber, Patricia A. [1 ]
Mehra, Mandeep R. [1 ]
机构
[1] Univ Maryland, Sch Med, Div Cardiol, Baltimore, MD 21201 USA
关键词
CARDIAC-RESYNCHRONIZATION THERAPY; LEFT-VENTRICULAR DYSFUNCTION; INITIATE LIFESAVING TREATMENT; CONVERTING ENZYME-INHIBITORS; ASSOCIATION TASK-FORCE; MYOCARDIAL-INFARCTION; NATRIURETIC PEPTIDE; DIASTOLIC DYSFUNCTION; SYSTOLIC FUNCTION; RANDOMIZED-TRIAL;
D O I
10.4065/mcp.2009.0494
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic heart failure (CHF) remains the only cardiovascular disease with an increasing hospitalization burden and an ongoing drain on health care expenditures. The prevalence of CHF increases with advancing life span, with diastolic heart failure predominating in the elderly population. Primary prevention of coronary artery disease and risk factor management via aggressive blood pressure control are central in preventing new occurrences of left ventricular dysfunction. Optimal therapy for CHF involves identification and correction of potentially reversible precipitants, target-dose titration of medical therapy, and management of hospitalizations for decompensation. The etiological phenotype, absolute decrease in left ventricular ejection fraction and a widening of QRS duration on electrocardiography, is commonly used to Identify patients at increased risk of progression of heart failure and sudden death who may benefit from prophylactic implantable cardioverter-defibrillator placement with or without cardiac resynchronization therapy. Patients who transition to advanced stages of disease despite optimal traditional medical and device therapy may be candidates for hemodynamically directed approaches such as a left ventricular assist device; in selected cases, listing for cardiac transplant may be warranted.
引用
收藏
页码:180 / 195
页数:16
相关论文
共 158 条
[1]   Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation [J].
Aaronson, KD ;
Schwartz, JS ;
Chen, TM ;
Wong, KL ;
Goin, JE ;
Mancini, DM .
CIRCULATION, 1997, 95 (12) :2660-2667
[2]   Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000, cases in the Acute Decompensated Heart Failure National Registry (ADHERE) [J].
Adams, KF ;
Fonarow, GC ;
Emerman, CL ;
LeJemtel, TH ;
Costanzo, MR ;
Abraham, WT ;
Berkowitz, RL ;
Galvao, M ;
Horton, DP .
AMERICAN HEART JOURNAL, 2005, 149 (02) :209-216
[3]   Prospective assessment of the occurrence of anemia in patients with heart failure: Results from the Study of Anemia in a Heart Failure Population (STAMINA-HFP) Registry [J].
Adams, Kirkwood F., Jr. ;
Patterson, John H. ;
Oren, Ron M. ;
Mehra, Mandeep R. ;
O'Connor, Christopher M. ;
Pina, Ileana L. ;
Miller, Alan B. ;
Chiong, Jun R. ;
Dunlap, Stephanie H. ;
Cotts, William G. ;
Felker, Gary M. ;
Schocken, Douglas D. ;
Schwartz, Todd A. ;
Ghali, Jalal K. .
AMERICAN HEART JOURNAL, 2009, 157 (05) :926-932
[4]   Effects of digoxin on morbidity and mortality in diastolic heart failure: The ancillary Digitalis Investigation Group trial [J].
Ahmed, Ali ;
Rich, Michael W. ;
Fleg, Jerome L. ;
Zile, Michael R. ;
Young, James B. ;
Kitzman, Dalane W. ;
Love, Thomas E. ;
Aronow, Wilbert S. ;
Adams, Kirkwood F., Jr. ;
Gheorghiade, Mihai .
CIRCULATION, 2006, 114 (05) :397-403
[5]   Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: A meta-analysis [J].
Allman, KC ;
Shaw, LJ ;
Hachamovitch, R ;
Udelson, JE .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (07) :1151-1158
[6]   Cardiac morphology and left ventricular function in normotensive morbidly obese patients with and without congestive heart failure, and effect of weight loss [J].
Alpert, MA ;
Terry, BE ;
Mulekar, M ;
Cohen, MV ;
Massey, CV ;
Fan, TM ;
Panayiotou, H ;
Mukerji, V .
AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 (06) :736-740
[7]   Obesity cardiomyopathy: Pathophysiology and evolution of the clinical syndrome [J].
Alpert, MA .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2001, 321 (04) :225-236
[8]   Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH):: randomised, double-blind, placebo-controlled trial [J].
Anand, I ;
McMurray, J ;
Cohn, JN ;
Konstam, MA ;
Notter, T ;
Quitzau, K ;
Ruschitzka, F ;
Lüscher, TF .
LANCET, 2004, 364 (9431) :347-354
[9]  
[Anonymous], 1990, Lancet, V336, P1
[10]  
[Anonymous], 1992, NEW ENGL J MED, V327, P685, DOI [10.1056/NEJM199209033271003.Erratumin, DOI 10.1056/NEJM199209033271003]